Carl W. Langren
Net Worth

Last updated:

What is Carl W. Langren net worth?

The estimated net worth of Mr. Carl W. Langren is at least $8,712,216 as of 12 Dec 2018. He has earned $814,326 from insider trading and has received compensation worth at least $7,897,890 in Lumos Pharma, Inc..

What is the salary of Carl W. Langren?

Mr. Carl W. Langren salary is $717,990 per year as Consultant in Lumos Pharma, Inc..

How old is Carl W. Langren?

Mr. Carl W. Langren is 70 years old, born in 1955.

What stocks does Carl W. Langren currently own?

As insider, Mr. Carl W. Langren owns shares in one company:

Company Title Shares Price per share Total value
Lumos Pharma, Inc. (LUMO) Consultant 19,666 $0 $0

What does Lumos Pharma, Inc. do?

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

Carl W. Langren insider trading

Lumos Pharma, Inc.

Mr. Carl W. Langren has made 6 insider trades between 2014-2018, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 9,523 units of LUMO stock on 21 Nov 2017. As of 12 Dec 2018 he still owns at least 19,666 units of LUMO stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 2,564 $0.8 $2,051
Option
Stock Option (Right to Buy) 2,564 $0.8 $2,051
Option
Stock Option (Right to Buy) 9,523 $2.1 $19,998
Option
Common Stock 9,523 $2.1 $19,998
Sale
Common Stock 2,229 $9.05 $20,172
Sale
Common Stock 3,943 $10.85 $42,782
Sale
Common Stock 1,095 $35.01 $38,336
Sale
Common Stock 9,500 $53 $503,500
Sale
Common Stock 3,587 $34.81 $124,867
Sale
Common Stock 2,827 $29.95 $84,669

Lumos Pharma key executives

Lumos Pharma, Inc. executives and other stock owners filed with the SEC: